ArticleThe journal of prevention of Alzheimer's disease2026
From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy.
Timo GrimmerPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.